SeekingAlpha · Jul 31, 2026
Diebold Nixdorf, Incorporated 2026 Q2 - Results - Earnings Call Presentation
2026-07-31. The following slide deck was published by Diebold Nixdorf, Incorporated in conjunction with their 2026 Q2 earnings call.
NYSE · DBD
Technology · Software - Application
$67.84
Up+$0.27 (+0.40%)
Updated Oct 21, 2026, 4:29 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DBD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
DBD closed at $67.84 after 21 trading sessions, up 5.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $67.89 | $68.95 | $67.55 | $67.84 | 167.14K |
| Oct 19, 2026 | $67.07 | $68.20 | $67.07 | $67.57 | 221.85K |
| Oct 16, 2026 | $66.70 | $67.56 | $65.9212 | $66.83 | 211.34K |
| Oct 15, 2026 | $64.16 | $66.88 | $63.77 | $66.57 | 188.73K |
| Oct 14, 2026 | $64.21 | $64.7999 | $63.67 | $64.29 | 188.45K |
| Oct 13, 2026 | $62.94 | $65.30 | $62.85 | $65.19 | 220.41K |
| Oct 12, 2026 | $63.39 | $64.235 | $63.12 | $63.26 | 173.25K |
| Oct 9, 2026 | $62.80 | $63.68 | $62.575 | $63.67 | 219.99K |
| Oct 8, 2026 | $64.78 | $65.05 | $62.59 | $63.02 | 242.5K |
| Oct 7, 2026 | $65.28 | $65.46 | $64.24 | $65.04 | 172.89K |
| Oct 6, 2026 | $66.42 | $67.1774 | $65.35 | $65.48 | 171.34K |
| Oct 5, 2026 | $63.77 | $67.28 | $63.77 | $65.63 | 392.71K |
| Oct 2, 2026 | $64.59 | $65.52 | $63.06 | $63.77 | 282.48K |
| Oct 1, 2026 | $61.53 | $63.51 | $61.01 | $63.18 | 333.34K |
| Sep 30, 2026 | $60.37 | $61.35 | $59.28 | $61.22 | 337.45K |
| Sep 29, 2026 | $61.11 | $61.85 | $59.88 | $60.25 | 238.09K |
| Sep 28, 2026 | $61.91 | $62.73 | $60.87 | $60.89 | 261.18K |
| Sep 25, 2026 | $63.01 | $63.325 | $62.3101 | $62.72 | 122.4K |
| Sep 24, 2026 | $62.85 | $63.42 | $62.34 | $62.47 | 173.58K |
| Sep 23, 2026 | $64.00 | $64.465 | $63.02 | $63.04 | 176.53K |
| Sep 22, 2026 | $64.32 | $64.975 | $63.98 | $64.39 | 226.39K |
The latest Smart Investors Daily articles mentioning DBD.
Company
Market Activity
Research & News
DBD research
Company profile and research snapshot.
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Wedbush | Outperform | — |
| May 4, 2026 | DA Davidson | Buy | — |
| Apr 21, 2026 | DA Davidson | Buy | — |
| Feb 13, 2026 | Wedbush | Outperform | — |
| Feb 13, 2026 | DA Davidson | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Jul 31, 2026
2026-07-31. The following slide deck was published by Diebold Nixdorf, Incorporated in conjunction with their 2026 Q2 earnings call.
SeekingAlpha · Jul 29, 2026
Diebold Nixdorf, Incorporated (DBD) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsMaynard Um - Vice President of Investor...
Benzinga · Jul 29, 2026
Diebold Nixdorf (NYSE:DBD) affirms FY2026 Adj EPS guidance from $5.25-$5.75 to $5.25-$5.75 vs $5.49 analyst estimate. Affirms FY2026 sales outlook from $3.860 billion-$3.940 billion to $3.860 billion-$3.940 billion vs
Benzinga · Jul 29, 2026
Diebold Nixdorf (NYSE:DBD) reported quarterly earnings of $1.10 per share which met the analyst consensus estimate. This is a 17.02 percent increase over earnings of $0.94 per share from the same period last year. The
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning DBD.